Your browser doesn't support javascript.
loading
A four-parameter index of marrow dysplasia has predictive value for survival in myelodysplastic syndromes.
Tassin, F; Dewé, W; Schaaf, N; Herens, C; Ravoet, C; Albert, A; Beguin, Y; Paulus, J M.
Afiliación
  • Tassin F; Department of Laboratory Hematology, CHU du Sart Tilman, University of Liège, Belgium.
Leuk Lymphoma ; 36(5-6): 485-96, 2000 Feb.
Article en En | MEDLINE | ID: mdl-10784393
ABSTRACT
Marrow dysplasia is a major characteristic of patients with myelodysplastic syndrome (MDS), along with marrow blastosis, cytopenia and cytogenetic anomalies. However, the impact of the degree of marrow dysplasia on survival has not been fully assessed. In this retrospective analysis of 111 patients selected according to the IPSS criteria of MDS diagnosis, the presence or absence of 21 dysplasia characteristics recognizable in bone marrow smears stained by the May-Grünwald-Giemsa method was correlated with patient survival. Using Cox proportional hazards regression analysis, megaloblastosis (MEGALO), neutrophil agranularity (AGRAN) and hypogranularity (HYPOGRAN) were highly significant predictors (p < 0.005), and Pelger-Huët anomaly (PELGHUET) a significant predictor (p = 0.05), of patient survival. The regression analysis yielded a dysplasia-based risk index (DI) where DI = 1.26 MEGALO + 0.82 AGRAN - 1.08 HYPOGRAN + 0.45 PELGHUET. The two subgroups of 60 and 47 patients with DI < or = 0 and > 0 showed highly significant differences in median survivals (2.6 vs 1.1 yrs; p <0.0001). Multivariate analysis further showed that DI offered additional predictive power that was independent of that provided by the IPSS (p=0.002 and 0.001 respectively). Analysis of survival curves stratified for IPSS and DI showed that the additional predictive power offered by inclusion of the DI essentially concerned the IPSS low/INT-1 risk categories. Further stratification for age did not improve survival prediction. The data indicate that a set of 4 dysplasia parameters can offer some prediction for survival of MDS patients in addition to that provided by the IPSS. Further multicenter studies should aim at including some form of evaluation of the degree of dysplasia in prognostic systems.
Asunto(s)
Buscar en Google
Bases de datos: MEDLINE Asunto principal: Médula Ósea / Síndromes Mielodisplásicos Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Leuk Lymphoma Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2000 Tipo del documento: Article País de afiliación: Bélgica
Buscar en Google
Bases de datos: MEDLINE Asunto principal: Médula Ósea / Síndromes Mielodisplásicos Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Leuk Lymphoma Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2000 Tipo del documento: Article País de afiliación: Bélgica